| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f6e33603375c486b0ab3505830af9e8 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2001-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6743f9742a635d86468ee5da1e3052bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4b55a6aa671ce3012788da16536daae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_833554f3c69c3cc63a93c8bd67f1f449 |
| publicationDate |
2002-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2002226398-A |
| titleOfInvention |
Antitumor composition containing anti-Fas antibody |
| abstract |
(57) [Problem] To provide a novel pharmaceutical composition useful as a novel antitumor agent having few side effects. SOLUTION: Mouse-mouse hybridoma HFE7 A (FERM BP-5828) produces anti-human Fa An antitumor composition comprising the monoclonal antibody HFE7A or a humanized antibody thereof as an active ingredient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2005228742-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005102363-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005102363-A2 |
| priorityDate |
2001-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |